Let's delve into the often overlooked yet critical topic of vaginal and vulval cancers, and the need for comprehensive quality guidelines to aid in their prevention and diagnosis.
The survival rates for these cancers are alarmingly low compared to more common women's cancers, highlighting a pressing issue that demands our attention. With only a handful of new cases diagnosed annually in Australia, it's no wonder these cancers pose unique challenges for healthcare professionals.
One of the primary reasons for the poor survival rates is the rarity of these cancers, which often leads to a lack of familiarity among clinicians. General practitioners, for instance, might encounter just one case, if any, during their entire career. This scarcity of exposure hampers early detection and effective management.
The Current Landscape
For more prevalent cancers like cervical, endometrial, and ovarian, Optimal Care Pathways (OCPs) have been developed, setting national standards for quality care. Research has shown that adhering to these OCPs can significantly improve survival rates, independent of new treatments or diagnostic tests. However, no such pathway currently exists for vaginal and vulvar cancers.
To address this gap, we conducted a systematic review to identify and evaluate existing guidelines on diagnostic pathways for these cancers. Our review focused on the first three stages of the OCP: prevention and early detection, presentation and initial investigations, and diagnosis.
Key Findings
Our review identified 45 guidelines internationally, with only two developed in Australia. Most guidelines covered prevention and early detection, but fewer addressed presentation and diagnosis. Consistent recommendations included HPV vaccination, opportunistic screening during cervical screening, and biopsy for suspected invasive lesions.
For diagnosis, guidelines recommended taking a patient's medical history, physical evaluation including vulvar and pelvic examination, and cytology testing with HPV testing and blood tests.
Referral to appropriate clinicians, such as gynecologists, was advised for concerning lesions or abnormal test results. Further investigations, including colposcopy and biopsy for histopathologic confirmation, were recommended for persistent vulvar symptoms.
Gaps and Recommendations
One notable gap in the current guidelines is the lack of incorporation of consumer views and preferences. To ensure guidelines are useful across various settings and address known inequities, consumers from priority groups should be included in the development of OCPs. This could help address disparities in care for Aboriginal and Torres Strait Islander people, those living in rural and remote areas, and older Australians.
Additionally, guidelines should address the applicability of recommendations by providing practical advice on implementation, describing potential resource implications, and suggesting methods for monitoring guideline uptake.
The creation of an OCP for vaginal and vulvar cancers in Australia could bridge these gaps, combining existing evidence and expert opinion. OCPs can enhance clinical practice by including consumer perspectives, providing specific recommendations for priority populations, and offering guidance for implementation.
Future Directions
Before developing new OCPs, it's essential to evaluate current screening practices. The National Cervical Screening Program, while primarily aimed at reducing cervical cancer, also offers an opportunity to detect vaginal and vulvar cancers through visual examination. The impact of self-collection for HPV screening, a strategy to reach under-screened women, should be considered, as it may limit opportunities for incidental findings during physical exams.
An OCP for vaginal and vulvar cancers can provide much-needed support to GPs, offering clear and standardized pathways for prevention and detection. Rare Cancers Australia is currently developing an OCP for rare and less common cancers, which could serve as a valuable resource.
In conclusion, the development of quality guidelines and OCPs is crucial for improving the prevention, diagnosis, and management of vaginal and vulvar cancers. By addressing the gaps identified in our review and incorporating consumer perspectives, we can work towards reducing disparities in care and improving survival rates for these often-overlooked cancers.
